Ongoing Clinical Trials
InGeneron is currently enrolling patients in clinical trials for the following indications:
- Partial Thickness Rotator Cuff Tear: This condition is one of the most common orthopedic impairments of a person’s shoulder, and can be characterized by a degenerative and often chronic condition found in the supraspinatus tendon.
- Facet Joint Syndrome: This condition is associated with the inflammation of a person’s facet joint, which leads to degeneration and cartilage loss. This condition causes chronic back pain – the major symptom of facet joint syndrome.
- Wrist Osteoarthritis: This indication can result in bone spurs and bone cysts in the wrist, as well as a degeneration of cartilage. It can cause inflammation and pain, and can lead to a reduction in grip strength and limited range of motion.
Participating in a Clinical Trial
All clinical trial designs differ and are customized to the specific indication. But generally, this is what you can expect if you participate in one of our clinical trials:
- You will be presented with a consent form and asked if you fully understand its content. You will then be asked to sign the form.
- Following that, you will be screened by a physician at a participating site to determine if you fulfill the inclusion criteria for the trial.
- If you fulfill the criteria and continue to be interested in participating, the complete clinical trial process and its interventions will be explained to you in detail.
- There will be no compensation for your participation in the trial.
- Our clinical trials are randomized. That means you will be randomly assigned to one of two groups: the group that will receive a cell therapy using the InGeneron platform, or the group that receives treatment using the current standard of care as described in the study protocol. Neither you nor the clinical team that follows you through the clinical trial will be informed as to which of these two groups you have been assigned. The chance of being assigned to the cell-therapy group, however, is at least 50 percent.
- Following the initial treatment—either the cell therapy or the currently available therapy—you will be monitored over an extended period of time. You will be asked to report on your health status and will need to see the treating physician for ongoing follow-up visits. The final visit typically occurs 12 months after the initial treatment, at which time you will be assessed in comparison to the assessment of the initial visit. The data that is gathered from this comparison will be analyzed to determine the benefit of the cell therapy relative to the current standard.
- When the trial is completed and its results are published, you can inquire as to which of the two groups described above you were randomly assigned.
Please contact us at firstname.lastname@example.org if you are interested in learning more about our clinical trials. Please be aware that only a small number of patients can participate in these trials and typically patients need to live close to a participating site.